NASDAQ:KRBP

Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement

Retrieved on: 
Tuesday, June 7, 2022
Data Management, Biotechnology, Technology, Health, Oncology, Other Technology, Research, Software, Genetics, Science, Clinical Trials, Company, GDT, Securities Exchange Act of 1934, Safety, LinkedIn, Food, Annual report, Neoplasm, IND, University, FDA, Private Securities Litigation Reform Act, Data mining, SRA, NASDAQ, SEC, Twitter, Drug development, Regulation of tobacco by the U.S. Food and Drug Administration, MD Anderson Cancer Center, Principal, PD-L1, Terminology, Pharmaceutical industry, Gamma delta T cell

Under the two-year SRA, in vivo preclinical data will be generated from Kiromics Gamma Delta T cell (GDT) allogeneic therapies.

Key Points: 
  • Under the two-year SRA, in vivo preclinical data will be generated from Kiromics Gamma Delta T cell (GDT) allogeneic therapies.
  • These submissions will expand the total number of our product candidate therapies to five.
  • We believe utilizing non-genetically engineered Gamma Delta T cells as our first-in-human study is ideal to establish the tolerability and safety of our proprietary allogeneic cell therapy platform.
  • Kiromic is in the process of developing a multi-indication gamma delta allogeneic T cell therapy treatment platform that exploits the natural potency of gamma delta T cells to target solid cancers.

Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, May 13, 2022
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Other Technology, Research, Software, Genetics, Science, Clinical Trials, Diamond, GDT, DNA, Software, Inc., Company, Immunotherapy, Drug discovery, Goal, NASDAQ, Clinical trial, CGMP, D, Kirom Bukhoroi, Good manufacturing practice, Neuro, Research, RVV, Securities Exchange Act of 1934, Board, Terminology, Technology, Drug development, Machine learning, LinkedIn, Lutheran Student Fellowship, Twitter, CAR, Data mining, SEC, Private Securities Litigation Reform Act, Cancer, Annual report, ALEXIS, Medical device, Mobile phone, Vaccine, Pharmaceutical industry, Gamma delta T cell

This past quarter has seen tremendous progress inside the Company, particularly within the research, development, and manufacturing functions.

Key Points: 
  • This past quarter has seen tremendous progress inside the Company, particularly within the research, development, and manufacturing functions.
  • We have a tremendous opportunity ahead of us, with incredible science that we are looking forward to ultimately making available to patients.
  • Quarter 1 Fiscal Year 2022 Financial Highlights:
    Cash Position: Cash and cash equivalents were $15,123,100 as of March 31, 2022, compared to $25,353,900 as of December 31, 2021.
  • The difference is attributable to cash outflows of $7,520,200, $2,541,800, and $168,800 for operating, investing, and financing activities, respectively.

Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Retrieved on: 
Wednesday, May 11, 2022
FDA, Technology, Pharmaceutical, Oncology, General Health, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Other Technology, Science, Biotechnology, Other Science, Health, Research, Drug development, IND, Twitter, NASDAQ, Data mining, Chemistry, Company, Securities Exchange Act of 1934, Cell engineering, FDA warning letter, CGMP, Clinical trial, FDA, Letter, GMP, Annual report, GDT, ALEXIS, Private Securities Litigation Reform Act, Cuernavaca, LinkedIn, CMC, Gamma delta T cell, SEC, Terminology, Kirom Bukhoroi, Pharmaceutical industry

A cGMP mammalian master cell bank is a significant step forward in the Companys clinical pathway and would address a key issue identified by the FDA in the clinical hold letter.

Key Points: 
  • A cGMP mammalian master cell bank is a significant step forward in the Companys clinical pathway and would address a key issue identified by the FDA in the clinical hold letter.
  • We are very pleased to share these significant regulatory updates, reflecting the progress we have been making as a Company.
  • From its heritage as a cancer vaccine development company, Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline.
  • We undertake no obligation to update any forward-looking statements except to the extent required by law.

Lifshitz Law PLLC Announces Investigations of Bumble Inc. (NASDAQ: BMBL), Kiromic BioPharma, Inc. (NASDAQ: KRBP), FirstCash Holdings, Inc. (NASDAQ: FCFS), and QuantumScape Corporation (NYSE: QS)

Retrieved on: 
Wednesday, April 13, 2022
Telephone, Life, Lists of schools in England, Defendant, Hewlett, Technology, Company, MLA, Advertising, Bumble, Complaint, KRBP, FCFS, QS, Online shopping, Online gambling, Badoo

If you are a BMBL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are a BMBL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • Lifshitz Law PLLC announces an investigation into alleged materially false and misleading statements made by KRBP in violation of federal securities law.
  • If you are a KRBP investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

Kiromic BioPharma Announces Availability of Company’s Current Corporate Presentation

Retrieved on: 
Monday, April 11, 2022
Research, Other Health, General Health, Pharmaceutical, Oncology, Technology, Medical Devices, Genetics, Science, Biotechnology, Other Technology, Health, Other Science, ALEXIS, Company, LinkedIn, NASDAQ, Marketing, Forward-looking statement, SEC, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Government, Security (finance), Artificial intelligence, Industry, Securities Exchange Act of 1934, Twitter, COVID-19, Intellectual property, Terminology, Annual report, Corporation, Pharmaceutical industry, Audit, Risk management

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (Kiromic or the Company), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND AI (artificial intelligence) and big data mining platform to discover, validate and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the availability of the Companys most recent corporate presentation.

Key Points: 
  • Kiromic BioPharma, Inc. (NASDAQ: KRBP) (Kiromic or the Company), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND AI (artificial intelligence) and big data mining platform to discover, validate and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the availability of the Companys most recent corporate presentation.
  • The updated presentation can be accessed on the investor relations section of the Companys website.
  • The corporate presentation was also filed as a Form 8-K with the Securities and Exchange Commission.
  • See the updated corporate presentation here Kiromic BioPharma April 2022 Corporate Presentation .

Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, April 8, 2022
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Other Technology, Research, Software, Genetics, Science, Clinical Trials, Diamond, CGMP, ALEXIS, Company, Cell, Drug development, LinkedIn, NASDAQ, Kirom Bukhoroi, D, Marketing, Immunotherapy, Forward-looking statement, Clinical trial, Research, SEC, Integration, Private Securities Litigation Reform Act, Government, Drug discovery, Industry, Database, Twitter, Securities Exchange Act of 1934, COVID-19, Inc., Intellectual property, Development, Terminology, Annual report, Lutheran Student Fellowship, Good manufacturing practice, Algorithm, Medical device, Pharmaceutical industry, Animal, Vaccine, Risk management, Audit

We are extremely encouraged by the progress the Company demonstrated in the fourth quarter.

Key Points: 
  • We are extremely encouraged by the progress the Company demonstrated in the fourth quarter.
  • We look forward to more opportunities to communicate with our shareholders as we demonstrate the Companys overall progress.
  • Fiscal Year Ended 2021 Financial Highlights:
    Cash Position: Cash and cash equivalents were $25,353,900 as of December 31, 2021, compared to $10,150,500 as of December 31, 2020.
  • The difference is attributable to cash outflows of $20,321,500, and $1,810,800 for operating activities, and investing activities, respectively.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Retrieved on: 
Monday, April 4, 2022
Company, NASDAQ, Fraud, Steve Berman (lawyer), CFO, SEC, Person, Program, Cancer, KRBP, IND, GLOBE, News, SAN, FDA, Pharmaceutical industry, Animal, Kirom Bukhoroi

The firm is investigating Kiromics possible securities law violations.

Key Points: 
  • The firm is investigating Kiromics possible securities law violations.
  • But on July 16, 2021, Kiromic disclosed that it had received comments from the FDA on its two INDs.
  • Finally, on Feb. 2, 2022, Kiromic essentially admitted that it had not been forthcoming with investors concerning the status of the INDs.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma, Inc. - KRBP

Retrieved on: 
Thursday, March 31, 2022
NASDAQ, Kirom Bukhoroi, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, GLOBE, News, COA, Private investigator

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma, Inc. (Kiromic or the Company) (NASDAQ: KRBP).

Key Points: 
  • NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma, Inc. (Kiromic or the Company) (NASDAQ: KRBP).
  • The investigation concerns whether Kiromic and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On or around October 16, 2020, Kiromic conducted its initial public offering, selling 1.25 million shares of common stock priced at $12.00 per share.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Retrieved on: 
Monday, March 28, 2022
Company, NASDAQ, Fraud, Steve Berman (lawyer), CFO, SEC, Person, Program, Cancer, KRBP, IND, GLOBE, News, SAN, FDA, Pharmaceutical industry, Animal, Kirom Bukhoroi

The firm is investigating Kiromics possible securities law violations.

Key Points: 
  • The firm is investigating Kiromics possible securities law violations.
  • But on July 16, 2021, Kiromic disclosed that it had received comments from the FDA on its two INDs.
  • Finally, on Feb. 2, 2022, Kiromic essentially admitted that it had not been forthcoming with investors concerning the status of the INDs.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

Kiromic Biopharma Announces Filing of Form 12b-25

Retrieved on: 
Friday, April 1, 2022
Research, Other Health, General Health, Pharmaceutical, Oncology, Technology, Medical Devices, Genetics, Science, Biotechnology, Other Technology, Health, Other Science, Company, Drug development, LinkedIn, NASDAQ, Kirom Bukhoroi, Form, Forward-looking statement, SEC, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Government, Industry, Securities Exchange Act of 1934, Twitter, COVID-19, Inc., Annual report, Terminology, Security (finance), Pharmaceutical industry, Audit

The Company expects to file its 2021 Form 10-K during the 15-calendar day extension period.

Key Points: 
  • The Company expects to file its 2021 Form 10-K during the 15-calendar day extension period.
  • Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases.
  • Kiromic is in the process of developing a multi-indication allogeneic CAR-T cell therapy that exploits the natural potency of Gamma Delta T-cells to target solid cancers.
  • From its heritage as a cancer vaccine development company, Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline.